Peptides DB
Research-centric peptide and protocol reference hub

KPV record · updated 17h ago

Healing & recoveryInflammation & immuneGrade A · human clinicalResearch use only
All 22 studiesJump to the evidenceCompare
What is KPV used for?

KPV is a tripeptide composed of lysine, proline, and valine, which has been studied for its potential immunomodulatory and wound healing properties. Its mechanism of action is thought to involve the modulation of inflammatory responses, potentially through the inhibition of pro-inflammatory cytokines and promotion of anti-inflammatory pathways. KPV may also enhance the healing process by promoting angiogenesis and fibroblast proliferation, which are critical for tissue repair.

How it works: Modulation of inflammatory responses

Primarily researched for · Healing & recovery

Development stage

where KPV sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 47 registered trials. It describes the research record, not a recommendation.

Identity
NameKPV
Chain length—
Molecular weight192.2 Da
FormulaC11H12O3
Structure typeSmall molecule
ClassHealing
Research levelPreclinical
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 13294447. No verified residue count for this compound.

Pharmacology
MechanismModulation of inflammatory responses
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 31, 2026. How this works →
Research stats
Total studies22
Human / animal / cellular11 / 3 / 3
Highest trial phasePreclinical
Years covered2010–2026
Latest study4d ago
Publication history
20102026
Research funding
6 NIH projects · $1.2M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

22 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.
FindingNot reported in abstract.
Animal2016Full text read0.80
Causes and timing of death in extremely premature infants from 2000 through 2011.
Finding275 deaths per 1000 live births from 2000 through 2003, 95% CI 264 to 285.
Human2015Full text read0.90
Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
FindingSurvival without moderate or severe bronchopulmonary dysplasia at 36 weeks was 16.6% in the hydrocortisone group and 13.2% in the placebo group.
Human2022Full text read0.90
Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
FindingIncidence of death or neurodevelopmental impairment was 52.5% in the erythropoietin group and 49.5% in the placebo group, relative risk 1.03, 95% CI 0.86 to 1.24, P=0.74.
Human2022Full text read0.90
Maternal potassium-magnesium sulfate supplementation in low-protein diets improves performance and health of sows and suckling piglets.
FindingWeaning-to-estrus interval decreased linearly with increasing PMS supplementation, p=0.022.
Animal2026Full text read0.80
Dissecting the evolutionary forces shaping codon usage bias in SFTSV from eastern China: Insights from a previously underrepresented region.
FindingNatural selection accounted for 52.8-91.4% of codon usage bias.
In vitro2026Full text read0.70
Metabolomic analysis of follicular fluid in women with unexplained infertility.
FindingSignificantly reduced levels of follicular 25-hydroxyvitamin D despite uniform oral supplementation.
Human2026Full text read0.80
Sulphur-containing amino acids promote the expression of <i>CG33474</i> and its neighbouring genes through the transsulphuration pathway.
FindingNot reported in abstract.
Animal2026Full text read0.70
Differential modulation of gentamicin antibacterial activity by vitamin B12 and vitamin D3 against Gram-positive and Gram-negative bacteria: an <i>in vitro-in silico</i> study.
FindingVitamin B12 reduced MICs by up to 8-fold.
In vitro2026Full text read0.70
Ovalbumin oxidative modification fingerprints depend on gas plasma-driven reactive species profiles.
FindingOver 80 distinct oxidative protein modifications mapped at per-amino-acid resolution.
In vitro2026Full text read0.80
Subspecies Identification and Characterization of Drug Resistance and Virulence Factors in Clinical Strains of <i>Mycobacterium abscessus</i> Complex Isolated from South India.
FindingMABC identified in 2.25% (n=25) of cases among 1110 clinical samples.
Human2026Full text read0.80
Spatial variability of soil attributes and risk of phosphorus loss in different soil classes of the Potengi River Basin, Brazil.
FindingNot reported in abstract.
—2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching KPV will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much KPV is discussed should be drawn from it.

Articles mentioning KPV